Show simple item record

dc.contributor.authorRustin, G
dc.contributor.authorReed, N
dc.contributor.authorJayson, Gordon C
dc.contributor.authorLedermann, J A
dc.contributor.authorAdams, M
dc.contributor.authorPerren, T
dc.contributor.authorPoole, C
dc.contributor.authorLind, M
dc.contributor.authorPersic, M
dc.contributor.authorEssapen, S
dc.contributor.authorGore, M
dc.contributor.authorCalvert, H
dc.contributor.authorStredder, C
dc.contributor.authorWagner, A
dc.contributor.authorGiurescu, M
dc.contributor.authorKaye, S
dc.date.accessioned2012-02-23T12:05:38Z
dc.date.available2012-02-23T12:05:38Z
dc.date.issued2011-11
dc.identifier.citationA phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. 2011, 22 (11):2411-6 Ann Oncolen
dc.identifier.issn1569-8041
dc.identifier.pmid21372124
dc.identifier.doi10.1093/annonc/mdq780
dc.identifier.urihttp://hdl.handle.net/10541/212349
dc.description.abstractSagopilone, the first fully synthetic epothilone, has shown promising preclinical activity in tumour models. This open-label randomised phase II study investigated two infusion schedules of sagopilone in women with ovarian cancer.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Agents
dc.subject.meshBenzothiazoles
dc.subject.meshDisease-Free Survival
dc.subject.meshDrug Administration Schedule
dc.subject.meshDrug Resistance, Neoplasm
dc.subject.meshEpothilones
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInfusions, Intravenous
dc.subject.meshMiddle Aged
dc.subject.meshOvarian Neoplasms
dc.titleA phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.en
dc.typeArticleen
dc.contributor.departmentMedical Oncology, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, UK.en
dc.identifier.journalAnnals of Oncologyen
html.description.abstractSagopilone, the first fully synthetic epothilone, has shown promising preclinical activity in tumour models. This open-label randomised phase II study investigated two infusion schedules of sagopilone in women with ovarian cancer.


This item appears in the following Collection(s)

Show simple item record